moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Representatives of Moleculin Biotech, Inc. (the Company) will use
the presentation set forth as Exhibit 99.1 herein in connection
with various meetings from time to time with the investment
community. The information contained in Item 7.01 of this Current
Report on Form 8-K, including Exhibit 99.1, is being furnished
and shall not be deemed to be filed for the purpose of the
Securities Exchange Act of 1934, as amended (Exchange Act), nor
shall it be deemed incorporated by reference in any filing under
the Exchange Act or the Securities Act of 1933, as amended,
unless specifically identified therein as being incorporated by
reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit No. | Description |
| 99.1 |
Moleculin Biotech, Inc. Investor Presentation dated February 28, 2017 |
About moleculin biotech, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations. moleculin biotech, INC. (NASDAQ:MBRX) Recent Trading Information
moleculin biotech, INC. (NASDAQ:MBRX) closed its last trading session down -0.06 at 1.14 with 229,228 shares trading hands.
